Bangalore-based Strides Arcolab Ltd and Eli Lilly, the world's largest manufacturer and distributor of psychiatric drugs, today announced that would collaborate to expand the delivery of cancer medicines in the emerging markets.
As part of the deal, Indianopolis, Indiana-based Eli Lilly will in-license a portfolio of high-quality, branded generic injectable and oral cancer medicines from Agila Specialties, the specialities division of Strides Arcolab.
Agila focuses on key domains such as oncolytics, penems, pencillins, cephalosporins, ophthalmics, peptides and biosimilars, and operates from 9 world-class global manufacturing facilities, including one of the largest steriles capacity in India and amongst the largest lyophilization (freeze drying) capacities in the world.
Agila's marketing network covers 70 countries and it has partnerships with some of the world's leading pharmaceutical companies for both developed and emerging markets.
Agila will manufacture the cancer drugs, while Eli Lilly will market them across emerging markets.
In addition to the initial 10 medicines included as part of the agreement, Lilly has the right to add additional high-quality branded generic oncology products to the portfolio in the future.